Related Experiment Video

Updated: May 10, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

RGS17: an emerging therapeutic target for lung and prostate cancers

Christopher R Bodle1, Duncan I Mackie, David L Roman

  • 1The Department of Pharmaceutical Sciences & Experimental Therapeutics, University of Iowa, College of Pharmacy, Iowa City, IA, USA.

Future Medicinal Chemistry
|June 6, 2013
PubMed

Insights

Regulator of G protein signaling (RGS) proteins, like RGS17, are crucial in cell signaling and cancer. High-throughput screening is identifying RGS inhibitors for potential cancer therapeutics.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • G-protein-coupled receptors (GPCRs) are key drug targets, with ligands comprising ~50% of marketed drugs.
  • Regulator of G protein signaling (RGS) proteins modulate GPCR signaling by regulating G protein activity.
  • RGS proteins, including RGS17, are increasingly recognized as potential therapeutic targets due to their roles in disease.

Purpose of the Study:

  • To highlight the significance of RGS proteins, particularly RGS17, as therapeutic targets.
  • To discuss the application of high-throughput screening in identifying RGS inhibitors.
  • To underscore the potential for developing targeted therapeutics based on RGS modulation.

Main Methods:

  • Review of existing literature on GPCRs, RGS proteins, and cancer biology.
  • Discussion of high-throughput screening technologies for drug discovery.
  • Analysis of RGS17's role in prostate, lung, and ovarian cancers.

Main Results:

  • RGS17 expression is linked to cancer progression and chemotherapeutic resistance.
  • High-throughput screening has successfully identified several RGS inhibitors.
  • Advancements in screening technologies promise novel lead compound discovery.

Conclusions:

  • RGS proteins represent promising targets for novel therapeutic strategies.
  • Targeted inhibition of RGS proteins, like RGS17, could offer new treatment avenues for various cancers.
  • Continued development of high-throughput screening will accelerate the discovery of RGS-targeted drugs.

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...